These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 36732210)

  • 1. Barriers and enablers to deprescribing for older people in care homes: The theory-based perspectives of pharmacist independent prescribers.
    Alharthi M; Wright D; Scott S; Birt L
    Res Social Adm Pharm; 2023 May; 19(5):746-752. PubMed ID: 36732210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Process evaluation for the Care Homes Independent Pharmacist Prescriber Study (CHIPPS).
    Birt L; Dalgarno L; Wright DJ; Alharthi M; Inch J; Spargo M; Blacklock J; Poland F; Holland RC; Alldred DP; Hughes CM; Bond CM;
    BMC Health Serv Res; 2021 Oct; 21(1):1041. PubMed ID: 34600542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing deprescribing: A qualitative understanding of the complexities of pharmacist-led deprescribing in care homes.
    Birt L; Wright DJ; Blacklock J; Bond CM; Hughes CM; Alldred DP; Holland R; Scott S
    Health Soc Care Community; 2022 Nov; 30(6):e6521-e6531. PubMed ID: 36336895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Everyone needs to understand each other's systems": Stakeholder views on the acceptability and viability of a Pharmacist Independent Prescriber role in care homes for older people in the UK.
    Lane K; Bond C; Wright D; Alldred DP; Desborough J; Holland R; Hughes C; Poland F
    Health Soc Care Community; 2020 Sep; 28(5):1479-1487. PubMed ID: 32124516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist-independent prescriber deprescribing in UK care homes: Contextual factors associated with increased activity.
    Alharthi M; Scott S; Alldred DP; Holland R; Hughes C; Birt L; Blacklock J; Bond C; Clark A; Wright D
    Br J Clin Pharmacol; 2023 Apr; 89(4):1509-1513. PubMed ID: 36516106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and enablers to deprescribing in long-term care: A qualitative investigation into the opinions of healthcare professionals in Ireland.
    Heinrich CH; McHugh S; McCarthy S; Donovan MD
    PLoS One; 2022; 17(12):e0274552. PubMed ID: 36520798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework.
    Evrard P; Pétein C; Beuscart JB; Spinewine A
    Implement Sci; 2022 Jul; 17(1):41. PubMed ID: 35804428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care homes: the CHIPPS study.
    Bond CM; Holland R; Alldred DP; Arthur A; Barton G; Blyth A; Desborough J; Ford J; Handford C; Hill H; Hughes CM; Maskrey V; Massey K; Myint PK; Norris N; Poland FM; Shepstone L; Turner D; Zermansky A; Wright D;
    Trials; 2020 Jan; 21(1):103. PubMed ID: 31964398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for the process evaluation of a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care home: the CHIPPS study.
    Bond CM; Holland R; Alldred DP; Arthur A; Barton G; Birt L; Blyth A; Desborough J; Ford J; Handford C; Hill H; Hughes CM; Maskrey V; Massey K; Myint PK; Norris N; Poland FM; Shepstone L; Zermansky A; Wright D;
    Trials; 2020 May; 21(1):439. PubMed ID: 32471514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation.
    Quek HW; Etherton-Beer C; Page A; McLachlan AJ; Lo SY; Naganathan V; Kearney L; Hilmer SN; Comans T; Mangin D; Lindley RI; Potter K
    Arch Gerontol Geriatr; 2023 Apr; 107():104910. PubMed ID: 36565605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Care Home Independent Prescribing Pharmacist Study (CHIPPS)-a non-randomised feasibility study of independent pharmacist prescribing in care homes.
    Inch J; Notman F; Bond CM; Alldred DP; Arthur A; Blyth A; Daffu-O'Reilly A; Ford J; Hughes CM; Maskrey V; Millar A; Myint PK; Poland FM; Shepstone L; Zermansky A; Holland R; Wright D;
    Pilot Feasibility Stud; 2019; 5():89. PubMed ID: 31338204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and enablers to deprescribing in long-term care facilities: a 'best-fit' framework synthesis of the qualitative evidence.
    Heinrich CH; Hurley E; McCarthy S; McHugh S; Donovan MD
    Age Ageing; 2022 Jan; 51(1):. PubMed ID: 35077555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers and enablers towards benzodiazepine-receptor agonists deprescribing in nursing homes: A qualitative study of stakeholder groups.
    Evrard P; Damiaens A; Patey AM; Grimshaw JM; Spinewine A
    Explor Res Clin Soc Pharm; 2023 Mar; 9():100258. PubMed ID: 37124470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a training programme for Pharmacist Independent Prescribers in a care home medicine management intervention.
    Birt L; Dalgarno L; Bond CM; Holland R; Alldred DP; Hughes C; Blyth A; Watts L; Wright DJ;
    BMC Med Educ; 2022 Jul; 22(1):551. PubMed ID: 35840960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What happens when pharmacist independent prescribers lead on medicine management in older people's care homes: a qualitative study.
    Birt L; Dalgarno L; Poland F; Wright D; Bond C
    BMJ Open; 2023 Oct; 13(10):e068678. PubMed ID: 37907299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers and enablers to monitoring and deprescribing opioid analgesics for chronic non-cancer pain: a systematic review with qualitative evidence synthesis using the Theoretical Domains Framework.
    Cross AJ; Buchbinder R; Mathieson S; Bourne A; Maher CG; Lin CC; O'Connor DA
    BMJ Qual Saf; 2022 May; 31(5):387-400. PubMed ID: 35064054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a hospital deprescribing implementation framework: A focus group study with geriatricians and pharmacists.
    Scott S; Twigg MJ; Clark A; Farrow C; May H; Patel M; Taylor J; Wright DJ; Bhattacharya D
    Age Ageing; 2019 Dec; 49(1):102-110. PubMed ID: 31711097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and Enablers of Deprescribing: A General Practitioner Perspective.
    Ailabouni NJ; Nishtala PS; Mangin D; Tordoff JM
    PLoS One; 2016; 11(4):e0151066. PubMed ID: 27093289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzodiazepine Use and Deprescribing in Belgian Nursing Homes: Results from the COME-ON Study.
    Evrard P; Henrard S; Foulon V; Spinewine A
    J Am Geriatr Soc; 2020 Dec; 68(12):2768-2777. PubMed ID: 32786002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprescribing Potentially Inappropriate Preventive Cardiovascular Medication: Barriers and Enablers for Patients and General Practitioners.
    Luymes CH; van der Kleij RM; Poortvliet RK; de Ruijter W; Reis R; Numans ME
    Ann Pharmacother; 2016 Jun; 50(6):446-54. PubMed ID: 26939589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.